Erastin: A Precise Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin is a potent, selective small molecule that induces ferroptosis, an iron-dependent form of non-apoptotic cell death, by inhibiting system X^c− and modulating the voltage-dependent anion channel (VDAC) (Yang et al., 2025). It exerts cytotoxicity in tumor cells harboring RAS (KRAS, HRAS) or BRAF mutations through lethal oxidative damage and increased reactive oxygen species (ROS). The compound is widely used in research on oxidative stress, cancer vulnerabilities, and the RAS-RAF-MEK signaling pathway. APExBIO provides Erastin (B1524) with defined solubility and stability parameters for robust experimental design. This article synthesizes mechanistic details, benchmark evidence, and workflow integration to support rigorous ferroptosis research.

Biological Rationale

Ferroptosis represents a distinct, iron-dependent modality of regulated cell death that differs from apoptosis, necrosis, and autophagy. It is characterized by the accumulation of lipid peroxides and catastrophic loss of plasma membrane integrity (Yang et al., 2025). RAS and BRAF oncogenic mutations sensitize tumor cells to ferroptosis, providing a therapeutic window for selective targeting [Contrast: This article provides direct protocol benchmarks, extending the translational focus in 'Erastin and the Next Frontier of Ferroptosis Research']. Conventional cell death inhibitors (e.g., caspase inhibitors) do not block ferroptosis, highlighting its unique mechanism. System X^c−, a cystine/glutamate antiporter, and glutathione peroxidase 4 (GPX4) are key metabolic gatekeepers that suppress ferroptotic death by maintaining redox homeostasis (Yang et al., 2025). Disruption of these systems leads to lethal accumulation of ROS and lipid hydroperoxides.

Mechanism of Action of Erastin

Erastin directly inhibits system X^c−, blocking cystine uptake and depleting intracellular glutathione (GSH) stores. This loss of GSH abrogates the antioxidant capacity of the cell and impairs GPX4 function, leading to unmitigated lipid peroxidation (Yang et al., 2025). Erastin also modulates VDAC, altering mitochondrial membrane permeability and further enhancing oxidative stress. The resulting accumulation of oxidized phospholipids (oxPLs), especially oxidized polyunsaturated fatty acid phospholipids (oxPUFA-PLs), triggers plasma membrane permeabilization and ferroptotic cell death. The process is independent of caspase activation and is not reversed by inhibitors of apoptosis or necroptosis [Contrast: This article details storage/solubility parameters, complementing the mechanistic insights in 'Erastin and the Translational Frontier'].

Evidence & Benchmarks

• Erastin induces ferroptosis in human tumor cell lines with KRAS or BRAF mutations at 10 μM, 24 h, leading to loss of viability via iron-dependent lipid peroxidation (Yang et al., 2025).
• Genetic ablation of TMEM16F, a phospholipid scramblase, sensitizes cells to Erastin-induced ferroptosis, implicating membrane remodeling in the execution phase (Yang et al., 2025).
• Erastin-triggered cell death is not prevented by pan-caspase inhibitors (e.g., z-VAD-fmk), supporting a caspase-independent mechanism (Yang et al., 2025).
• Erastin is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with gentle warming, facilitating cell-based assays (APExBIO Product Sheet).
• Long-term storage of Erastin solutions at room temperature leads to degradation; solid form is stable at -20°C (APExBIO Product Sheet).
• In TMEM16F-deficient tumors, Erastin combined with PD-1 blockade potentiates immune rejection, highlighting translational potential (Yang et al., 2025).

Applications, Limits & Misconceptions

Erastin is a reference compound for ferroptosis research, widely applied in cancer biology, oxidative stress assays, and studies of the RAS-RAF-MEK pathway. It enables the dissection of iron-dependent, caspase-independent cell death in both basic and translational oncology studies [Contrast: This article provides detailed physicochemical and workflow parameters, extending the immunomodulation focus in 'Erastin as a Precision Tool for Ferroptosis']. Erastin is not effective in all cell types; sensitivity is strongly associated with specific oncogenic mutations and redox states. It does not induce apoptosis or necroptosis and is ineffective where system X^c− is non-essential or redundant. Erastin is not a direct therapeutic but a research tool; in vivo use requires further toxicological validation.

Common Pitfalls or Misconceptions

• Erastin does not induce apoptosis or necroptosis; effects are specific to ferroptosis pathways.
• Cells lacking system X^c− activity or expressing high levels of alternative antioxidant systems (e.g., FSP1, DHODH) may show resistance.
• Improper storage (e.g., Erastin in solution at room temperature) rapidly leads to loss of activity.
• Erastin is not a clinical drug; it is for research use only.
• Solubility is limited to DMSO; attempts to dissolve in water or ethanol are ineffective.

Workflow Integration & Parameters

APExBIO's Erastin (B1524) is supplied as a solid compound with a molecular weight of 547.04 g/mol and formula C₃₀H₃₁ClN₄O₄. For typical cell-based assays, dissolve Erastin in DMSO to ≥10.92 mg/mL at 25–37°C with gentle warming. Prepare working solutions fresh, as DMSO stocks degrade over days at room temperature. Store powder at -20°C for maximal stability. The standard experimental condition is 10 μM Erastin applied to engineered human tumor cells or HT-1080 fibrosarcoma cells for 24 hours. Assays for cell viability, lipid peroxidation (e.g., C11-BODIPY staining), and ROS (e.g., DCFDA) are recommended endpoints (Yang et al., 2025). Include iron chelators (e.g., deferoxamine) and apoptosis/necroptosis inhibitors as negative controls to confirm pathway specificity.

Conclusion & Outlook

Erastin is a validated ferroptosis inducer and reference tool for probing iron-dependent, non-apoptotic cell death in cancer biology. It enables precise dissection of oxidative stress pathways and the vulnerabilities of RAS/BRAF-mutant tumors. As new mechanisms such as TMEM16F-mediated lipid scrambling emerge, Erastin will remain central to both bench research and the development of ferroptosis-based therapeutic strategies. For further details, see the Erastin product page at APExBIO. This article builds on and extends the translational and mechanistic analyses found in recent thought-leadership content on ferroptosis research [see 'Erastin and the Translational Edge' for broader clinical context].